Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00215449 · ClinicalTrials.gov registry record · Phase 3
Study in Patients With COPD
A Phase 3 study, sponsored by Dey.
- Completed
- Registry status
- Phase 3
- Development phase
- 690
- Enrollment target
NCT00215449: Completed Phase 3 study, sponsored by Dey.
NCT00215449 is a Phase 3 study that has completed, run by Dey. The registered enrollment target is 690 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (11% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00215449, a Phase 3 study, has completed, sponsored by Dey.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 690 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy and safety of the investigational drug in the treatment of COPD in comparison with a placebo.
Interventions
- DRUG Formoterol Fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 690 participants |
| Est. Completion | 2006-04 |
| Phase | Phase 3 |
What the finished NCT00215449 record still lists
NCT00215449 is an interventional study that assigns participants to a tested intervention. The registered 690 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (11% lower).
The record links to 0 conditions, and to 1 intervention - of which Formoterol Fumarate is the first listed.
NCT00215449 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00215449 about?
NCT00215449 is a clinical study titled "Study in Patients With COPD". The purpose of this study is to determine the efficacy and safety of the investigational drug in the treatment of COPD in comparison with a placebo.
What is the current status of trial NCT00215449?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 690 participants. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00215449?
The interventions under investigation include: Formoterol Fumarate (DRUG).
Who is sponsoring clinical trial NCT00215449?
This trial is sponsored by Dey, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00215449's enrollment target sits among peer trials
690 524th of 2000 higher than 1,476 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00532051 · 690 participants
Intraocular Lens Power Calculation After Laser Refractive Surgery Based on Optical Coherence Tomography
- NCT05184335 · 690 participants · Phase 3
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
- NCT07221149 · 690 participants · Phase 2
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- NCT07382167 · 692 participants · Phase 3
A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults